USPTO Examiner REDDIG PETER J - Art Unit 1646

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19276860COMPOSITIONS AND METHODS RELATED TO GPRC5D BINDING AGENTS AND VARIANTS THEREOFJuly 2025October 2025Allow300NoNo
18953634METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLSNovember 2024November 2025Allow1220NoNo
18409191IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19January 2024December 2025Abandon2310NoNo
18570578ANTI-CD3 CONSTRUCTS AND USES THEREOFDecember 2023October 2024Allow1010YesNo
18484244METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLSOctober 2023May 2024Allow710YesNo
18374956ENGINEERED IMMUNE CELLS TARGETING BCMA AND THEIR USES THEREOFSeptember 2023September 2025Allow2410YesNo
18363417CHIMERIC ANTIGEN RECEPTORS TARGETING ABNORMAL GLYCOBIOLOGYAugust 2023May 2025Allow2210NoNo
18331556IMPROVED DUAL SPECIFICITY POLYPEPTIDE MOLECULEJune 2023January 2026Abandon3120NoNo
18331859ANTI-CD20 ANTIBODY AND USES THEREOFJune 2023November 2025Allow2920NoNo
18331855ANTI-CD20 ANTIBODY AND USES THEREOFJune 2023September 2025Allow2720NoNo
18331862ANTI-CD20 ANTIBODY AND USES THEREOFJune 2023January 2026Allow3220NoNo
18206269CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH CD33 TARGETING AGENTSJune 2023August 2025Abandon2711NoNo
18321820IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODSMay 2023April 2025Allow2310NoNo
18322450CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USEMay 2023October 2025Abandon2810NoNo
18314727IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODSMay 2023April 2025Allow2310NoNo
18309303LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINSApril 2023August 2025Allow2810NoNo
18304956TREATMENT OF CANCER USING CHIMERIC CD3 RECEPTOR PROTEINSApril 2023July 2025Abandon2710NoNo
18297562ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGENApril 2023July 2025Abandon2701NoNo
18192715B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSMarch 2023March 2025Allow2410NoNo
18189443B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSMarch 2023February 2025Allow2310NoNo
18189448B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSMarch 2023February 2025Allow2310NoNo
18120020EXPRESSION AND SECRETION SYSTEMMarch 2023May 2025Abandon2610NoNo
18042763MODIFIED CAS9 SYSTEM HAVING A DOMINANT NEGATIVE EFFECTOR ON NON-HOMOLOGOUS END-JOINING FUSED THERETO AND ITS USE FOR IMPROVED GENE EDITINGFebruary 2023September 2025Allow3031YesNo
18170154B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSFebruary 2023August 2024Allow1700NoNo
18158754A CELL LEXPRESSING TWO CHIMERIC ANTIGEN RECEPTORS (CARS) AT THE CELL SURFACEJanuary 2023April 2025Allow2720YesNo
18147981UTILIZATION OF CD39 AND CD103 FOR IDENTIFICATION OF HUMAN TUMOR REACTIVE T CELLS FOR TREATMENT OF CANCERDecember 2022April 2025Allow2711YesNo
18064880TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORSDecember 2022October 2025Abandon3411NoNo
18061805METHODS FOR CANCER TREATMENTDecember 2022April 2025Abandon2910NoNo
18059746COMPOSITIONS, ASSAYS, AND METHODS FOR DIRECT MODULATION OF FATTY ACID METABOLISMNovember 2022March 2025Allow2711YesNo
18056572CD8-SPECIFIC ANTIBODY CONSTRUCTS AND COMPOSITIONS THEREOFNovember 2022March 2025Allow2811YesNo
18055188BCMA BINDING MOLECULES AND METHODS OF USE THEREOFNovember 2022April 2025Abandon2910NoNo
18049470ANTI-CD276 POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORSOctober 2022April 2025Abandon3010NoNo
17907648CHIMERIC ANTIGEN RECEPTORS TARGETING CD33September 2022November 2025Allow6010YesNo
17954070METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPYSeptember 2022May 2025Allow3121YesNo
17953114Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses ThereofSeptember 2022November 2025Allow3710YesNo
17904941ENGINEERED T CELL RECEPTORS AND METHODS OF USEAugust 2022March 2026Allow4211NoNo
17801458NOVEL METHODS FOR CREATING ALPHA-N-METHYLATED POLYPEPTIDESAugust 2022March 2026Abandon4310NoNo
17817308CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOFAugust 2022July 2025Allow3620YesNo
17816986USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENTAugust 2022January 2025Abandon3001NoNo
17791415METHOD AND ANTIBODY FOR DETECTION OF HBCAGJuly 2022January 2026Allow4320YesNo
17853576CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMAJune 2022October 2023Allow1631YesNo
17849561RECEPTOR-BASED ANTAGONISTS OF THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAYJune 2022October 2025Abandon4021NoNo
17788723CHIMERIC ANTIGEN RECEPTORS THAT BIND TO PROSTATE SPECIFIC MEMBRANE ANTIGENJune 2022January 2025Allow3040YesNo
17847909MULTIPLE ANTIGEN BINDING MOLECULAR FUSION, PHARMACEUTICAL COMPOSITION, METHOD FOR IDENTIFYING LINEAR EPITOPE, AND METHOD FOR PREPARING MULTIPLE ANTIGEN BINDING MOLECULAR FUSIONJune 2022April 2025Allow3411NoNo
17832290IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODSJune 2022September 2024Allow2710NoNo
17829183METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORSMay 2022August 2025Abandon3811NoNo
17826557IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODSMay 2022September 2024Allow2710NoNo
17826583IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODSMay 2022January 2025Abandon3210NoNo
17745067CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGENMay 2022September 2024Allow2810NoNo
17734512DNA VACCINE AGAINST AMYLOID-BETA AND TAUMay 2022December 2025Abandon4410NoNo
17732232PEPTIDE-HINGE-FREE FLEXIBLE ANTIBODY-LIKE MOLECULEApril 2022March 2025Allow3520YesNo
17725240COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCERApril 2022September 2025Allow4120NoNo
17720766Anti-FOLR1 Immunoconjugate Dosing RegimensApril 2022September 2025Abandon4120NoYes
17718975Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of CancerApril 2022August 2024Allow2910NoNo
17718513BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF BLADDER CANCERApril 2022February 2026Abandon4711NoNo
17716547COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCERApril 2022December 2024Abandon3310NoNo
17716026NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERSApril 2022August 2024Allow2810NoNo
17655519FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCERMarch 2022October 2025Allow4330YesNo
17692838NEUTRALIZING ANTIBODIES TO SARS-COV-2 AND ITS VARIANTSMarch 2022May 2025Abandon3831YesNo
17689698FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAMEMarch 2022September 2024Allow3010YesNo
17681139COMPOSITIONS TARGETING THE INTERACTION DOMAIN BETWEEN P27KIP1 AND BRK AND METHODS OF USE THEREOF TO INHIBIT P27 Y PHOSPHORYLATION AND CDK4 ACTIVITYFebruary 2022August 2024Allow2911YesNo
17665117NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERSFebruary 2022November 2024Abandon3410NoNo
17586984ANTIBODIES BINDING TO GPRC5DJanuary 2022November 2025Abandon4610NoNo
17649200METHODS OF TREATING CANCERS WITH CT45 TARGETED THERAPIESJanuary 2022August 2024Allow3011YesNo
17630391METHOD FOR TREATMENT OF HEPATIC CANCER USING REIC/Dkk-3 GENE IN COMBINATION WITH ANTI-TUMOR AGENTJanuary 2022November 2025Abandon4670NoNo
17628118CHIMERIC ANTIGEN RECEPTOR T CELLS AND USES THEREOFJanuary 2022June 2025Abandon4101NoNo
17557607IMMUNE CELL COMPOSITIONS AND METHODS OF USEDecember 2021July 2024Allow3011NoNo
17596879CULTURE DEVICEDecember 2021October 2025Abandon4611NoNo
17550219BISPECIFIC BINDING PROTEINS AND USES THEREOFDecember 2021November 2024Abandon3510NoNo
17535898THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCERNovember 2021March 2026Abandon5121NoYes
17609972Ultraspecific Cell Targeting Using De Novo Designed Co-Localization Dependent Protein SwitchesNovember 2021February 2026Abandon5111NoNo
17521335IMMUNOREGULATORY AGENTNovember 2021September 2024Allow3521YesNo
17438051DETECTION MEANS, COMPOSITIONS AND METHODS FOR MODULATING SYNOVIAL SARCOMA CELLSSeptember 2021January 2026Abandon5221NoNo
17469549PD-1 POLYPEPTIDE VARIANTSSeptember 2021October 2025Allow4951NoNo
17464528CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELLSeptember 2021February 2025Allow4220NoNo
17420739BISPECIFIC IN TANDEM RECEPTOR CAR AND METHOD FOR MODULATING THE TUMORAL MICROENVIRONMENTJuly 2021June 2025Allow4821YesNo
17364270HYBRID IMMUNOGLOBULIN CONTAINING NONPEPTIDYL LINKAGEJune 2021August 2025Allow4921NoNo
17292102METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS FOR THE TREATMENT OF FIBROSISMay 2021February 2026Abandon5730NoNo
17290065METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGENApril 2021August 2025Allow5121YesNo
17288406TCR AND PEPTIDESApril 2021December 2024Abandon4401NoNo
17238059ENHANCED ANTIGEN PRESENTING ABILITY OF RNA CAR T CELLS BY CO-INTRODUCTION OF COSTIMULATORY MOLECULESApril 2021July 2024Allow3921NoNo
17228843METHOD FOR ENHANCING PRODUCTION OF GENETICALLY ENGINEERED AUTOLOGOUS T CELLSApril 2021October 2024Allow4311YesNo
17284407COMPOSITIONS AND METHODS FOR SWITCHABLE CAR T CELLS USING SURFACE-BOUND SORTASE TRANSPEPTIDASEApril 2021November 2024Allow4320YesNo
17250988LET-7 PROMOTES ANTI-TUMOR ACTIVITY OF CD8 T CELLS AND MEMORY FORMATION IN VIVOApril 2021October 2025Abandon5421NoNo
17280471CD22 CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIESMarch 2021November 2024Abandon4401NoNo
17280202CD146 AND USES THEREOF AS A BIOMARKER AND AS A THERAPEUTIC TARGET IN THE DIAGNOSIS AND TREATMENT OF FIBROSISMarch 2021January 2025Allow4511YesNo
17202173DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY BY PD-1 BLOCKADEMarch 2021August 2025Allow5341NoNo
17202018THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOFMarch 2021November 2024Allow4431YesNo
17262180Individualized Vaccines for CancerJanuary 2021December 2025Allow5921NoNo
17152031ANTI-TUMORAL COMPOSITIONJanuary 2021November 2024Abandon4630NoNo
17257469CHIMERIC RECEPTORS IN COMBINATION WITH TRANS METABOLISM MOLECULES ENHANCING GLUCOSE IMPORT AND THERAPEUTIC USES THEREOFDecember 2020January 2025Abandon4832NoNo
16950296ANTI-CD79 CHIMERIC ANTIGEN RECEPTORS, CAR-T CELLS, AND USES THEREOFNovember 2020September 2025Allow5841YesNo
17051341OCA-B PEPTIDE CONJUGATES AND METHODS OF TREATMENTOctober 2020July 2024Allow4520YesNo
17063505TREATMENT OF VIRAL INFECTIONOctober 2020March 2025Abandon5310NoNo
17061998ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATESOctober 2020July 2025Allow5731NoNo
17028608Payload-Polymer-Protein ConjugatesSeptember 2020February 2025Abandon5321NoNo
17025732METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLSSeptember 2020October 2024Allow4921YesYes
16975725Treatment and prevention of pre-eclampsiaAugust 2020October 2024Abandon5010NoNo
16969381CHIMERIC ANTIGEN RECEPTOR THERAPY IN COMBINATION WITH IL-15R AND IL15August 2020October 2024Abandon5041NoNo
16968547CYCLIN A1 SPECIFIC T CELL RECEPTORS AND USES THEREOFAugust 2020November 2025Allow6021YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner REDDIG, PETER J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
2
(66.7%)
Examiner Reversed
1
(33.3%)
Reversal Percentile
49.3%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
26
Allowed After Appeal Filing
4
(15.4%)
Not Allowed After Appeal Filing
22
(84.6%)
Filing Benefit Percentile
18.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner REDDIG, PETER J - Prosecution Strategy Guide

Executive Summary

Examiner REDDIG, PETER J works in Art Unit 1646 and has examined 210 patent applications in our dataset. With an allowance rate of 88.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner REDDIG, PETER J's allowance rate of 88.1% places them in the 68% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by REDDIG, PETER J receive 2.95 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by REDDIG, PETER J is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +18.6% benefit to allowance rate for applications examined by REDDIG, PETER J. This interview benefit is in the 61% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.6% of applications are subsequently allowed. This success rate is in the 33% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 52.7% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 85.0% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 70.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 61.5% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 21.4% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 17.3% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.